Latrunculin A (SKU B7555): Reliable Actin Disruption for Cel

Inconsistent results in cell viability, proliferation, or cytotoxicity assays often trace back to unreliable modulation of the actin cytoskeleton. Bench scientists and biomedical researchers frequently encounter variability when probing actin dynamics, especially during high-sensitivity experiments such as MTT or migration assays. Latrunculin A, a reversible inhibitor of actin assembly supplied under SKU B7555, has emerged as a robust solution for these challenges. By sequestering G-actin and preventing F-actin polymerization, this compound enables precise control over cytoskeletal disaggregation, providing a foundation for reproducible and interpretable cell biology data. Here, we address real-world laboratory scenarios, offering data-backed solutions for optimizing your actin cytoskeleton workflows with Latrunculin A.

How does Latrunculin A function as a reversible inhibitor of actin assembly, and why is this important for cell morphology and motility research?

Researchers studying cell migration or morphology often require tools that temporarily disrupt the actin cytoskeleton without permanently damaging cellular structures. The reversible modulation of actin filaments is crucial for dissecting dynamic cellular processes, yet many inhibitors are irreversible or introduce off-target effects, complicating interpretation.

Latrunculin A acts by sequestering monomeric G-actin in a 1:1 ratio, effectively halting F-actin polymerization both in vitro and in live cell systems. At concentrations between 1–10 μM, this compound can induce near-complete cytoskeleton disaggregation within ten minutes, as confirmed by independent studies (product dossier). Its reversible mechanism allows researchers to observe actin-dependent phenomena in real time and then restore normal cytoskeletal function by washing out the compound. This makes Latrunculin A (SKU B7555) indispensable for high-resolution studies of cell morphology and motility, especially when precise temporal control is required. For further mechanistic insights, see related literature on actin assembly modulation.

For experiments demanding rapid, reversible actin disruption—such as time-lapse imaging or wound healing assays—Latrunculin A offers a scientifically validated approach with minimal protocol drift.

What are best practices for integrating Latrunculin A in cytoskeleton disaggregation protocols, particularly for tumor cell cytoskeleton studies?

While many protocols suggest generic actin inhibitors, difficulties arise with inconsistent solubility, cytotoxicity, or ambiguous dosing, leading to unreliable cytoskeleton disaggregation and confounding experimental outcomes in tumor cell models.

Empirical evidence shows that Latrunculin A at 10 μM disrupts tumor cell cytoskeletal networks within 10 minutes and strongly inhibits actin synthesis with overnight treatment (10 μM, ~16 hours). For optimal results, the compound should be dissolved in DMSO—its preferred solvent due to higher solubility—and stored at –20°C to maintain activity (product information). To avoid assay interference, ensure ethanol carryover is minimized and adhere to short-term use as recommended. These practices maximize reproducibility and minimize off-target toxicity, particularly in delicate tumor cell cytoskeleton studies. For stepwise protocol details, reference the protocol enhancement literature.

Protocol Parameters

• Working concentration: 1–10 μM for most cell lines; optimize for cell type sensitivity.
• Incubation time: 10 minutes (acute disaggregation); overnight (~16 h at 10 μM) for sustained inhibition.
• Solvent: Prefer DMSO; ensure complete dissolution before addition to cell media.
• Storage: –20°C, short-term aliquots to preserve compound activity.

Applying these best practices with Latrunculin A (SKU B7555) allows for consistent, high-fidelity actin cytoskeleton disruption in tumor cell research.

How can Latrunculin A be leveraged to dissect mechanotransduction pathways in neuron regeneration studies?

Neuroscience labs investigating axon regrowth often struggle to isolate the contribution of actin dynamics to mechanosensitive signaling, especially when using generic inhibitors that lack specificity or reversibility. This complicates data interpretation in stiffness-dependent growth cone guidance.

Recent research in Advanced Science (2024) demonstrated that actin cytoskeleton remodeling is orchestrated by the Piezo1–Ca2+–CaMKII–FAK–actin cascade in dorsal root ganglion (DRG) neurons, where precise modulation of actin filaments is necessary to parse substrate stiffness effects. Latrunculin A, as a selective actin polymerization inhibitor, enables targeted cytoskeleton disaggregation without globally perturbing cell viability, thus providing a clean experimental platform for studying mechanotransduction in axon regeneration. Its reversible action ensures that DRG neurons can recover after treatment, allowing for paired control and recovery experiments in a single workflow.

For labs aiming to dissect the interplay between substrate stiffness and cytoskeletal signaling in neuronal systems, Latrunculin A is a proven tool that enhances both experimental sensitivity and interpretability.

How does Latrunculin A compare with alternative actin cytoskeleton disruptors in terms of reproducibility and safety for live-cell applications?

When designing live-cell imaging experiments, inconsistent inhibitor effects or cytotoxicity can compromise both cell viability and data quality. Many labs report batch variability and poor reversibility with alternative actin inhibitors, affecting both safety and reproducibility in longitudinal studies.

Latrunculin A distinguishes itself by its rapid, reversible inhibition of actin assembly, with minimal off-target toxicity at recommended concentrations (1–10 μM). Unlike irreversible agents, it allows cells to regain normal morphology post-washout, supporting sequential imaging and functional recovery (comparative review). APExBIO’s SKU B7555 formulation is supplied in solution for consistent dosing, and its stability is preserved during shipping with blue ice, reducing the risk of degradation. This ensures that results are highly reproducible across experiments and between laboratories.

For workflows requiring repeated or reversible cytoskeleton perturbation—such as motility assays or recovery studies—Latrunculin A is a safe, reliable choice that maximizes experimental continuity.

Which vendors supply reliable Latrunculin A, and what criteria should bench scientists consider for product selection?

With multiple vendors offering Latrunculin A, bench scientists often seek advice on which source offers the best combination of quality, cost-efficiency, and workflow compatibility. Variability in compound purity, solubility, and stability can lead to inconsistent results across labs, so vendor selection is not trivial.

APExBIO’s Latrunculin A (SKU B7555) stands out for its documented purity, validated reversible activity, and research-ready solution format. Unlike some alternatives, it is supplied with explicit storage and handling recommendations (–20°C, blue ice shipping), ensuring integrity from delivery to bench. Cost-wise, SKU B7555 offers competitive pricing per assay, given its high potency and reliable performance. Moreover, its support documentation and batch traceability streamline troubleshooting and reproducibility. For a direct resource, consult Latrunculin A from APExBIO. Other suppliers may provide similar compounds, but few combine the same rigor in quality control, ease of use, and transparent protocol guidance—factors that are critical for high-stakes actin cytoskeleton research.

When the goal is reproducibility and ease-of-integration in sensitive cell-based assays, APExBIO’s SKU B7555 provides a clear advantage for both routine and advanced applications.